Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors

Rhea-AI Summary

Day One Biopharmaceuticals (Nasdaq: DAWN) has commenced dosing the first patient in a Phase 2 clinical trial evaluating DAY101 as a monotherapy for patients with RAF-altered solid tumors. DAY101 is a pan-RAF kinase inhibitor targeting the MAPK pathway. The multi-center study, FIRELIGHT-1, aims to assess the safety and efficacy of DAY101 with an overall response rate as the primary endpoint. Day One plans to initiate a Phase 1b combination study with its MEK inhibitor, pimasertib, in Q1 2022, while continuing to gather data from a pivotal trial in pediatric low-grade glioma patients.

Positive

• DAY101 has shown promising anti-tumor activity in patients with specific MAPK alterations.
• The Phase 2 trial expands DAY101's use beyond pediatric low-grade glioma, addressing broader patient needs.
• DAY101 has received Breakthrough Therapy designation from the FDA for certain pediatric patients.

Negative

• Reliance on the success of ongoing trials introduces regulatory and market risks.
• Potential delays in clinical trial results could impact investor confidence.

• Phase 1b/2 Study Evaluating DAY101 in Combination with Pimasertib, Day One’s MEK Inhibitor, Expected to Begin in First Quarter of 2022

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating DAY101 as a monotherapy in patients with RAF-altered solid tumors. DAY101 is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway.

“DAY101 has demonstrated encouraging anti-tumor activity as a monotherapy in patient populations where MAPK pathway alterations are believed to play an important role in driving disease progression,” said Samuel Blackman, M.D., Ph.D., co-founder and chief medical officer of Day One. “Expanding the development of DAY101 beyond pediatric low-grade glioma represents an important step in our overall development strategy for this promising program, and we look forward to enrolling additional RAF-altered solid tumor patients in this Phase 2 monotherapy study.”

The multi-center, open-label umbrella study, FIRELIGHT-1, will evaluate the safety and efficacy of DAY101 in patients with recurrent or progressive solid tumors with activating RAF alterations. This study will accrue adults as well as adolescent patients as young as 12 years of age. In the Phase 2 monotherapy portion, patients will be enrolled either into a melanoma cohort or a "tissue agnostic" cohort, and will receive oral DAY101 at a dose of 600mg once weekly. The primary endpoint will be overall response rate (ORR) as assessed by RECIST version 1.1 criteria. Secondary and exploratory endpoints include safety, duration of response, progression-free survival, and time to response. Additional information may be found at ClinicalTrials.gov, using Identifier NCT04985604.

Day One expects to initiate a Phase 1b combination portion of the study with the Company’s oral MEK inhibitor, pimasertib, in the first quarter of 2022. Day One also continues to enroll patients in a pivotal Phase 2 clinical trial (FIREFLY-1) of DAY101 in pediatric, adolescent and young adults with recurrent or progressive low-grade glioma (pLGG) harboring a known BRAF alteration (NCT04775485), with initial data expected in the first half of 2022.

About DAY101
DAY101 is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway. Studies have shown DAY101 has high brain distribution and exposure in comparison to other MAPK pathway inhibitors, thus potentially benefiting patients with primary brain tumors or brain metastases of solid tumors. DAY101 is a type II RAF inhibitor found to selectively inhibit both monomeric and dimeric RAF kinase, which may broaden its potential clinical application to treat an array of RAF-altered tumors.

DAY101 has been studied in over 250 patients, and as a monotherapy demonstrated good tolerability and encouraging anti-tumor activity in pediatric and adult populations with specific MAPK pathway-alterations. In November 2020, Day One announced preliminary results from PNOC014, an ongoing Phase 1 Pacific Pediatric Neuro-Oncology Consortium (PNOC) network study with DAY101 sponsored by the Dana-Farber Cancer Institute. Preliminary results demonstrated that of the eight relapsed pLGG patients in the study with RAF fusions, two patients achieved a complete response by Response Assessment for Neuro-Oncology (RANO), three had a partial response, two achieved prolonged stable disease, and one experienced progressive disease. DAY101 also demonstrated a tolerable safety profile with the most common side effects being skin rash and hair color changes.

DAY101 has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with pLGG harboring an activating RAF alteration who require systemic therapy and who have either progressed following prior treatment or who have no satisfactory alternative treatment options. The FDA has also granted Rare Pediatric Disease Designation to DAY101 for the treatment of low-grade gliomas harboring an activating RAF alteration that disproportionately affects children. In addition, DAY101 has received Orphan Drug designation from the FDA for the treatment of malignant glioma and orphan designation from the European Commission for the treatment of glioma.

Day One is conducting a pivotal Phase 2 trial (FIREFLY-1) of DAY101 in pediatric, adolescent and young adult patients with pLGG. Day One also plans to study DAY101 alone or in combination with other agents that target key signaling nodes in the MAPK pathway, such as the Company’s MEK inhibitor pimasertib, in patient populations where various RAS and RAF alterations are believed to play an important role in driving disease.

About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Our name was inspired by the “The Day One Talk”¹ that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. We aim to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule designed to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco. For more information, please visit www.dayonebio.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Day One’s plans to develop cancer therapies, expectations from current clinical trials, the execution of the Phase 2 clinical trial for DAY101 as designed, any expectations about safety, efficacy, timing and ability to complete clinical trials and to obtain regulatory approvals for DAY101 and other candidates in development, and the ability of DAY101 to treat pLGG or related indications.

Statements including words such as “believe,” “plan,” “continue,” “expect,” “will,” “develop,” “signal,” “potential,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.

Forward-looking statements are subject to risks and uncertainties that may cause Day One’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in our filings with the Securities and Exchange Commission, including Day One’s ability to develop, obtain regulatory approval for or commercialize any product candidate, Day One’s ability to protect intellectual property, the potential impact of the COVID-19 pandemic and the sufficiency of Day One’s cash, cash equivalents and investments to fund its operations. These forward-looking statements speak only as of the date hereof and Day One specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

¹Jennifer W. Mack and Holcombe E. Grier; Journal of Clinical Oncology 2004 22:3, 563-566

Contacts:

Media:
1AB
Dan Budwick
dan@1abmedia.com

Investors:
LifeSci Advisors
Hans Vitzthum
hans@lifesciadvisors.com

FAQ

What is the current status of DAY101 trials as of November 2021?

As of November 2021, the first patient has been dosed in the Phase 2 trial for DAY101 targeting RAF-altered solid tumors.

What are the primary goals of the FIRELIGHT-1 study with DAY101?

The FIRELIGHT-1 study aims to evaluate the safety and efficacy of DAY101, focusing on the overall response rate as the primary endpoint.

When is the Phase 1b study with pimasertib expected to begin?

The Phase 1b study with pimasertib is expected to start in the first quarter of 2022.

What designations has DAY101 received from the FDA?

DAY101 has received Breakthrough Therapy designation, Rare Pediatric Disease Designation, and Orphan Drug designation from the FDA.

How does DAY101's mechanism of action work?

DAY101 is a highly-selective type II pan-RAF kinase inhibitor that targets key enzymes in the MAPK signaling pathway.